Science 37, the US-based developer of a clinical trials facilitation platform, secured $29m in yesterday in a series C round that included internet technology conglomerate Alphabet and pharmaceutical companies Sanofi and Amgen.
Growth equity firm Glynn Capital Management led the round, which also featured DRx Capital, the joint venture formed by pharmaceutical firm Novartis and semiconductor producer Qualcomm, as well as Lux Capital and Redmile Group.
GV, Sanofi and Amgen participated in the round through their respective corporate venturing subsidiaries, GV, Sanofi Ventures and Amgen Ventures.
Science 37 has created a software platform called Network Oriented Research Assistant (NORA) that decentralises the clinical trials process, making it easier for patients to access them from their own homes through mobile devices or telemedicine services.
Noah Craft, Science 37’s co-founder and chief executive, said: “The new funding will help us drive continued expansion and recruit top talent from both the technology and from the clinical trial industries.
“The round will also allow us to expand into new therapeutic areas and to introduce these trials to a much broader set of demographics, including those with limited access to major medical facilities where these trials are typically offered.”
The round boosted Science 37’s overall funding to $66.5m, and comes after a $31m series B round led by Redmile that included DRx Capital, Lux Capital and Sanofi subsidiary Sanofi Genzyme BioVentures in October 2016.
DRx Capital and Lux Ventures had co-led the company’s $6.5m series A round a year earlier.